GLP-1 community claims on TikTok: what holds up?

What did @simplybridget12 actually say?

In a candid, phone-side video, @simplybridget12 told a friend not to take Ozempic, partly as a joke to keep supply for herself, but also made a handful of real claims worth examining. She said constipation is manageable with water, fiber, and a supplement called "Dusanal Lus." She argued weight regain after stopping GLP-1s is tied to "hormonal metabolic dysfunction" and doesn't happen to everyone. And she brought up what she called a new study showing GLP-1s could "reduce breast cancer cells," calling it a reason alone to stay on the medication. She also mentioned picking up a three-month supply of "menjaro" (Mounjaro/tirzepatide) while half-joking about quitting it too.

The tone is conversational and self-aware, but the health claims land in real territory. Some hold up reasonably well. Others are stretched or need serious context before anyone should factor them into a medication decision.

Does the science back this up?

On constipation: yes, fiber, hydration, and osmotic laxatives are legitimate first-line strategies, and the evidence supports them. On weight regain: she's directionally right that metabolic biology drives it, but her framing oversimplifies. On the breast cancer claim: there is early-stage data, but calling it a reason to start or stay on a GLP-1 is a significant leap.

The constipation advice is grounded. A 2023 review in Obesity Reviews (Blundell et al.) confirmed GI side effects including constipation are among the most reported with semaglutide, and standard management includes increased fluid intake and dietary fiber. The supplement she names, likely psyllium-based, is a reasonable fiber source, though "Dusanal Lus" is not a recognized clinical product name and couldn't be independently verified.

On weight regain, the STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who stopped semaglutide regained roughly two-thirds of lost weight within a year. The mechanism is real: GLP-1 receptors influence appetite and metabolic rate in ways that don't permanently reset. Her "hormonal metabolic dysfunction" framing is informal but not wrong in spirit.

The breast cancer claim references what appears to be early-stage preclinical or epidemiological data. A 2024 study published in eClinicalMedicine (Sarfati et al.) found associations between semaglutide use and reduced breast cancer incidence in large insurance databases, but this is observational and nowhere near proof of causation. "Reduce breast cancer cells" is not what the study concluded.

What did they get wrong (or right)?

She got the broad strokes of weight regain right, but her framing that some people simply don't have "hormonal metabolic dysfunction" and can therefore maintain weight without the drug is misleading. The STEP 4 data doesn't carve out a clean subgroup of people who keep weight off effortlessly after stopping. Most people regain, full stop.

The gym analogy she uses, comparing GLP-1 cessation to quitting the gym, is actually one of the more useful plain-language explanations of why weight regain happens. It's not perfect physiology, but it communicates the dependency correctly.

Where she goes furthest off track is the breast cancer statement. Saying that early data on GLP-1s and breast cancer is a reason to be on the medication conflates promising preliminary signals with established benefit. The American Cancer Society and FDA have not approved any GLP-1 for cancer prevention. Telling a general audience that this finding alone "makes me want to be on a GLP-1" without context could encourage people to start or continue medication based on unvalidated claims.

Her point that obesity is associated with 13 types of cancer is accurate. The CDC and National Cancer Institute both list excess body weight as a risk factor for at least 13 cancers, including breast, colon, and endometrial.

What should you actually know?

GLP-1 medications are legitimate, well-studied tools for weight management and type 2 diabetes, and the side effect profile is real but manageable for many people. Constipation is common and responding with fiber and fluids is appropriate first-line advice. Weight regain after stopping is the norm, not the exception, and that's a conversation to have with a prescriber before starting, not after months of use.

The breast cancer data is genuinely interesting to researchers. A 2024 analysis in JAMA Network Open (Nørgaard et al.) also found reduced cancer incidence in GLP-1 users, but these studies cannot establish that the drug prevents cancer. Confounding factors, including healthier behaviors in GLP-1 users, make it impossible to isolate the drug's effect at this stage.

If you're considering a GLP-1 medication, side effects, stopping risks, and potential benefits should come from a licensed provider who knows your health history, not a TikTok comment section. This video has good intentions and some real facts mixed in, but it's not a substitute for a clinical conversation.